1. Switzerland Stocks

  2. •

    Consumer non-durables

  3. •

    Food: specialty/candy
EvoNext Holdings SA

EvoNext Holdings SA

2.40
CHF
0.00
(0.00%)
5.84MMarket Cap
Feb 19Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.55
6.66
5.58
4.6
3.55
2.9
3.76
2.4
2.81
3.63
1.75
- -
- -
- -
Basic EPS, GAAP
-13.65
-15.33
-18.93
-18.92
-20.21
-9.48
-7.02
-9.49
-11.72
-10.13
-19.5
0.14
-0.09
- -
Free Cash Flow per Basic Share
-11.72
-15.18
-19.94
-18.41
-18.75
-11.84
-6.34
-9.2
-9.54
-4.94
-1.8
-0.34
-0.16
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
66.97
105.43
107.4
90.9
71.68
63.01
55.64
44.96
33.07
23.78
0.77
0.91
0.82
0.82
Tangible Book Value per Share
14.41
22.57
37.11
21.71
31.25
17.96
12.45
6.57
4.63
3.04
0.77
0.91
0.82
0.82
Basic Weighted Avg Shares
1
1
2
2
2
3
3
3
4
4
5
7
7
7
Sales/Revenue/Turnover
9
9
9
9
7
9
12
8
10
16
9
- -
- -
- -
Operating Margin (%)
-203.16
-265.21
-422.26
-480.09
-655.79
-344.09
-173.57
-330.27
-425.5
-259.93
-533.65
- -
- -
- -
Depreciation Expense
3
4
7
7
5
5
8
8
9
8
5
- -
- -
- -
Net Income, GAAP
-16
-21
-32
-36
-39
-29
-22
-30
-41
-43
-105
1
-1
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-180.7
-230.03
-339.29
-411.2
-569.28
-327.05
-186.61
-396.12
-417.78
-279.07
-1,114.98
- -
- -
- -
Working Capital
22
49
81
51
95
52
36
18
18
11
7
7
6
6
LT Debt
3
4
4
4
2
2
5
4
4
3
- -
- -
- -
- -
Total Equity
83
175
203
173
221
194
173
145
132
106
6
7
6
6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12.98
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
17.25
- -
- -
Return on Common Equity (%)
-22.28
-16.82
-17.02
-19.3
-19.89
-14.08
-11.8
-18.81
-29.81
-36.44
-188.26
17.18
-10.41
- -

Capital Structure

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
7
7
7
Market Capitalization
6
8
6

Working Capital

CHF

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
8
7
7
Cash, Cash Equivalents & STI
7
6
6
Accounts Receivable, Net
- -
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-14.09%
-22.89%
-9.9%
Free Cash Flow
-19.29%
-40.64%
-53.14%
Net Income, GAAP
-6.94%
-15.53%
-162.53%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
9
2024
- -
- -
- -
2025
- -
- -
- -

Semi-annual Earnings Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-19.5
2024
- -
- -
0.14
2025
- -
- -
-0.09

Semi-annual Dividends Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Gerhard Lobmaier
Full Time Employees
49
Sector
Consumer non-durables
Industry
Food: specialty/candy
Address
Angensteinerstrasse 6 Reinach BL Switzerland 4153
IPO Date
May 3, 2005
Website
evonextholdings.com
Similar Companies
PepsiCo, Inc. (NASDAQ:PEP)
Britannia Industries Ltd (NSE:BRITANNIA)
Tata Consumer Products Limited (NSE:TATACONSUM)
Ulker Biskuvi Sanayi A.S. (BIST:ULKER)
Mondelez International, Inc. (NASDAQ:MDLZ)
The Hershey Company (NYSE:HSY)
Business
EvoNext Holdings S.A. EvoNext Holdings SA (EVE.SW) operates as a holding company managing remaining assets following the divestment of its biotechnology operations. Incorporated in 2001 and headquartered in Reinach, Switzerland, the company previously focused on the discovery, research, development, and commercialization of nature-based ingredients for flavor and fragrances; health ingredients; health protection products; and other sectors, serving customers in Switzerland, the United States, and internationally through technology platforms combining biology and engineering as well as tailored technology services. It targets industries including novel food, nutritional, healthcare, and wellness segments with high-purity, sustainable ingredients produced via biotechnological processes. In a major strategic shift, EvoNext Holdings S.A. sold its main operating subsidiary, Evolva AG, to a subsidiary of Lallemand Inc. in December 2023, transitioning from active biotechnology research to asset liquidation and management. Shareholders approved a name change from Evolva Holding SA to EvoNext Holdings SA in July 2025 at an extraordinary general meeting. The board continues to pursue mergers and acquisitions, including reverse takeovers and a public offer to acquire GZO AG that expired in July 2025, alongside publishing its half-year report for 2025 detailing ongoing M&A explorations.